𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence

✍ Scribed by Manuel Ramos-Casals; Candido Diaz-Lagares; Maria-Jose Soto-Cardenas; Pilar Brito-Zeron; María-José Cuadrado; Giovanni Sanna; Laura Bertolaccini; Munther A. Khamashta

Book ID
107568501
Publisher
Humana Press Inc
Year
2010
Tongue
English
Weight
589 KB
Volume
40
Category
Article
ISSN
1080-0549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Histopathologic and clinical outcome of
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
✍ Iva Gunnarsson; Birgitta Sundelin; Thorunn Jónsdóttir; Stefan H. Jacobson; Elisa 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells. Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be of benefit in B cell–dependent diseases, including systemic lupus erythematosus (SLE). The purpose

Synchronised therapy and high-dose cyclo
Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis
✍ Maria Giovanna Danieli; Carla Palmieri; Aldo Salvi; Maria Cristina Refe; Anna St 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

The aim of this open study was to compare the outcomes and side effects of plasmapheresis (PP) in patients with proliferative lupus nephritis treated with cyclophosphamide (Cyc) boluses. The study involved 28 consecutive patients. All of the patients met the ACR modified criteria for SLE and underwe